Bioviva

First Successful Gene Therapy Against Human Aging? It May Be So

Posted by

0


Should these results prove to be accurate, it means that scientists have actually managed to create a way to reverse aging.

Meet Elizabeth Parrish

The CEO of Bioviva USA Inc, Elizabeth Parrish, claims to be the first human in world history to have successfully reversed the effects of natural aging—thanks to experimental gene therapy provided by her company.

Parrish first underwent gene therapy in 2015—one designed to protect against muscle mass depletion that is inherent to aging and another to fight stem cell depletion due to age-related diseases.

Originally meant to prove that her company’s gene therapy was safe, the results—should they prove to be effective in the long-term and withstand due scientific scrutiny—would be the very first successful demonstration of telomere lengthening in any human.

“Current therapeutics offer only marginal benefits for people suffering from diseases of aging. Additionally, lifestyle modification has limited impact for treating these diseases. Advances in biotechnology is the best solution, and if these results are anywhere near accurate, we’ve made history,” Parrish notes.

To that end, even Parrish is clear that more investigation is necessary in order to verify the methods; however, if verified, this work will be revolutionary.

BioViva aims to provide regenerative medicine to the masses through gene and cell therapies.
BioViva aims to provide regenerative medicine to the masses through gene and cell therapies.

Telomeres: How They Work

Telomeres are short segments of DNA that are found on the ends of each chromosome. These act as “buffers” for the wear and tear of natural aging. But with sustained cell division, telomeres eventually get too short to protect the chromosome. When this happens, it causes the call to malfunction and leads to aging.

The basis for the success of Parrish’s gene therapy is related to the telomere scores—which are calculated based on the telomere length in white blood cells (T-lymphocytes). Higher telomere scores indicate “younger cells.” Compared to average T-lymphocytes of the American population within the same age range, 44 year old Parrish claims that the gene therapies she underwent worked and showed that it reversed 20 years of telomere shortening.

As stated, it’s important to note that the results have yet to be verified by an independent source (which is really what science is all about). And Bioviva is still carefully monitoring Parrish’s blood and will continue to do so in the coming months, and even years, to ensure that the success it has seen in leukocytes can translate to the body’s other tissues and organs; or simply if the effects can be safely replicated in other human patients.

First Successful Gene Therapy Against Human Aging? It May Be So

Posted by

0


IN BRIEF

Should these results prove to be accurate, it means that scientists have actually managed to create a way to reverse aging.

MEET ELIZABETH PARRISH

The CEO of Bioviva USA Inc, Elizabeth Parrish, claims to be the first human in world history to have successfully reversed the effects of natural aging—thanks to experimental gene therapy provided by her company.

Parrish first underwent gene therapy in 2015—one designed to protect against muscle mass depletion that is inherent to aging and another to fight stem cell depletion due to age-related diseases.

Originally meant to prove that her company’s gene therapy was safe, the results—should they prove to be effective in the long-term and withstand due scientific scrutiny—would be the very first successful demonstration of telomere lengthening in any human.

“Current therapeutics offer only marginal benefits for people suffering from diseases of aging. Additionally, lifestyle modification has limited impact for treating these diseases. Advances in biotechnology is the best solution, and if these results are anywhere near accurate, we’ve made history,” Parrish notes.

To that end, even Parrish is clear that more investigation is necessary in order to verify the methods; however, if verified, this work will be revolutionary.

BioViva aims to provide regenerative medicine to the masses through gene and cell therapies.
BioViva aims to provide regenerative medicine to the masses through gene and cell therapies.

TELOMERES: HOW THEY WORK

Telomeres are short segments of DNA that are found on the ends of each chromosome. These act as “buffers” for the wear and tear of natural aging. But with sustained cell division, telomeres eventually get too short to protect the chromosome. When this happens, it causes the call to malfunction and leads to aging.

The basis for the success of Parrish’s gene therapy is related to the telomere scores—which are calculated based on the telomere length in white blood cells (T-lymphocytes). Higher telomere scores indicate “younger cells.” Compared to average T-lymphocytes of the American population within the same age range, 44 year old Parrish claims that the gene therapies she underwent worked and showed that it reversed 20 years of telomere shortening.

As stated, it’s important to note that the results have yet to be verified by an independent source (which is really what science is all about). And Bioviva is still carefully monitoring Parrish’s blood and will continue to do so in the coming months, and even years, to ensure that the success it has seen in leukocytes can translate to the body’s other tissues and organs; or simply if the effects can be safely replicated in other human patients.

First Human Being Has Their DNA Manipulated To Make White Blood Cells 20 Years Younger!

Posted by

0


Elizabeth Parris, the CEO of “Bioviva” USA Inc, has become the very first human being to successfully, from a biological standpoint, reverse the  age of her white blood cells, thanks to her own company’s experimental therapies.

“Bioviva” utilizes intramural and extramural peer-reviewed research to create therapies for age-related diseases (Parkinson’s, Alzheimer’s, cancer, heart-disease), and now, they have reversed 20 years of ‘telomere shortening’ in a human for the first time.

Telomeres are short segments of DNA that cap the ends of every chromosome and act as a protective feature against wear and tear, which occurs naturally as the human body ages. As we age, these telomeres become shorter and shorter as our cells continue to divide more and more. Eventually they become too short to protect the chromosome, which is what causes our cells to malfunction and age related diseases to start setting in. And that’s what we call aging.Telomeres and Aging

In September of last year, the 44 year old volunteered to partake in two of her own company’s experimental gene therapies; one intended to battle stem cell depletion, which happens when we age and leads to various age related diseases, and the other intended to protect against loss of muscle mass with age.

 After the gene therapy was completed on Parrish, the company’s website revealed the astonishing results of the experiment:
“In March 2016, the same tests were taken again by SpectraCell revealed that her telomeres had lengthened by approximately 20 years, from 6.71kb to 7.33kb. This implies that Parrish’s white blood cells (leukocytes) have become biologically younger. These findings were independently verified by the Brussels-based non-profit HEALES (HEalthy Life Extension Company), and the Biogerontology Research Foundation, a UK-based charity committed to combating age-related diseases.”

After learning of the experiment’s success, Parrish remarked that “if these results are anywhere near accurate, we’ve made history.”

The company will continue to monitor her blood in the months and years to come, and will be testing new gene therapies to restore age related damage.

Researchers still need to determine if the success seen in leukocytes can be extended to other organs and tissues, as well as repeated in other patients. For now, this is the first and only instance of such therapy being used (and successful) on a human, and was intended to prove the safety of this technique.

Long term scientific scrutiny is still necessary to say for certain whether this is a safe and viable procedure, but what’s happened so far is almost unbelievable.

It’s a very promising discovery, and one that has already attracted attention from various investment and scientific communities. One example is Deep Knowledge Life Sciences (DKLS), a UK investment fund company which has already made BioViva a portfolio company of theirs.

According to Parish, “the best-case scenario would be that we added 20 years of health onto the leukocytes, and the immune system might be more productive and catch more of the bad guys. But we have to wait and find out. The proof will be in the data,” she said.